Creative Commons source reading · Headache and migraine
Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study.
Piero Barbanti; Licia Grazzi; Gabriella Egeo; Anna Maria Padovan; Eric Liebler; Gennaro Bussone
Originally published in The journal of headache and pain · 2015-06-30
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background The treatment of migraine headache is challenging given the lack of a standardized approach to care, unsatisfactory response rates, and medication overuse. Neuromodulation therapy has gained interest as an alternative to pharmacologic therapy for primary headache disorders. This study investigated the effects of non-invasive vagus nerve stimulation (nVNS) in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). Findings In this open-label, single-arm, multicenter study, patients with HFEM or CM self-treated up to 3 consecutive mild or moderate migraine attacks that occurred during a 2-week period by delivering two 120-s doses of nVNS at 3-min intervals to the right cervical branch of the vagus nerve. Of the 50 migraineurs enrolled (CM/HFEM: 36/14), 48 treated 131 attacks. The proportion of patients reporting pain relief, defined as a ≥50% reduction in visual analog scale (VAS) score, was 56.3% at 1 h and 64.6% at 2 h. Of these patients, 35.4% and 39.6% achieved pain-free status (VAS = 0) at 1 and 2 h, respectively.
Methods
In this open-label, single-arm, multicenter study, 50 patients aged 18 to 65 years who were experiencing HFEM or CM [1, 13] were consecutively enrolled between February 1, 2013, and October 1, 2013, at the Headache and Pain Unit of the IRCCS San Raffaele Pisana in Rome, Italy, and the Headache Center of the Carlo Besta Neurological Institute and Foundation in Milan. The study protocol was approved by the San Raffaele Pisana institutional review board (10/2013), and all patients who were enrolled in the study provided written informed consent.
Results
We enrolled 50 patients (female/male: 40/10) affected by CM (n = 36) and HFEM (n = 14) (Table 1). Two patients with CM did not treat any migraine attacks; the remaining 48 patients treated a total of 131 attacks. Specifically, 30 patients with CM and 6 with HFEM treated 3 attacks each; 4 patients with CM and 7 with HFEM treated 2 attacks each; and 1 patient with HFEM treated 1 attack. After nVNS, 27 of 48 patients (56.3 %) reported pain relief at 1 h; of these patients, 35.4 % (n = 17) were pain free. Thirty-one patients (64.6 %) reported pain relief at 2 h, of which 39.6 % (n = 19) were pain free (Fig. 1).
Discussion
Results from the present study validate prior evidence that shows nVNS is effective for the acute treatment of migraine attacks in patients with HFEM or CM [11]. With enrollment of a larger (N = 50), more severely affected population who experienced more migraine attacks (N = 131), our research extends data from previous studies that showed a 2-h pain-free response of 22 % [11].
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
